Table 2.
Pulmonary signs and symptoms before hydrogen therapy of advanced non-small cell lung cancer patients with H2 inhalation treatment
| Control (n = 10) | H2 only (n = 10) | Immuno-H2 (n = 10) | Target-H2 (n = 18) | Chemo-H2 (n = 10) | P-value | |
|---|---|---|---|---|---|---|
| Respiratory function | ||||||
| FEV1 (L) | 1.57±0.59 | 1.63±0.52 | 1.54±0.59 | 1.56±0.49 | 1.56±0.52 | 0.3897 |
| FVC (L) | 1.82±0.57 | 1.93±0.47 | 1.75±0.33 | 1.83±0.56 | 1.91±0.35 | 0.4623 |
| KPS score | 76±7 | 78±8 | 76±7 | 77±7 | 78±8 | 0.4007 |
| Tumor-associated symptoms | ||||||
| Moderate cough | 6 | 7 | 5 | 2 | 3 | 0.0137 |
| Mild dyspnea | 5 | 5 | 2 | 3 | 2 | 0.0757 |
| Non-cardiac chest pain | 4 | 4 | 2 | 4 | 2 | 0.6666 |
| Mild pleural effusion | 3 | 3 | 1 | 3 | 2 | 0.748 |
| Mild hemoptysis | 2 | 2 | 0 | 3 | 0 | 0.3683 |
Note: Data are expressed as mean ± SD or number. Respiratory function and the KPS score were compared using one-way analysis of variance and Bonferroni’s multiple comparison tests. Tumor-associated symptoms were compared using chi-squared and Fisher’s exact tests. H2: hydrogen; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; KPS: Karnofsky performance status.